RCS - Envision Pharma Grp - Envision Names Dr. Jaggi to Board of Directors
09/05/2023 13:15
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230509:nRSI6343Ya&default-theme=true RNS Number : 6343Y Envision Pharma Group 09 May 2023 Envision Pharma Group Announces Appointment of Dr. Deepti Sodhi Jaggi to Board of Directors PHILADELPHIA, PA / ACCESSWIRE / May 9, 2023 / Envision Pharma Group (Envision) today announced the appointment of Dr. Deepti Sodhi Jaggi to the Envision Board of Directors. "We are pleased to welcome Deepti to the Envision Board of Directors," shares Meg Heim, CEO of Envision Pharma Group. "Deepti's deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner." Dr. Jaggi's career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan. Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies. Dr. Jaggi's previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area. "I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives," says Dr. Jaggi. Dr. Jaggi's educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business. About Envision Pharma Group Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com (https://pr.report/6sgD83bU) . Contact Information Colleen Carter Associate Director, Communications, Office of the CEO colleen.carter@envisionpharma.com (mailto:colleen.carter@envisionpharma.com) 1 (508) 505 8856 SOURCE: Envision Pharma Group This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NRAZELFBXELEBBD